Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

130.87USD
20 Feb 2018
Change (% chg)

$-2.28 (-1.71%)
Prev Close
$133.15
Open
$132.87
Day's High
$133.42
Day's Low
$130.68
Volume
1,663,817
Avg. Vol
2,196,005
52-wk High
$148.32
52-wk Low
$118.32

Chart for

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $357,562.41
Shares Outstanding(Mil.): 2,684.00
Dividend: 0.84
Yield (%): 2.52

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Johnson & Johnson Medical Devices Companies Acquire Orthotaxy

* JOHNSON & JOHNSON MEDICAL DEVICES COMPANIES ACQUIRE ORTHOTAXY TO DEVELOP NEXT-GENERATION ROBOTIC-ASSISTED SURGERY PLATFORM IN ORTHOPAEDICS‍​

20 Feb 2018

FDA approves J&J prostate cancer treatment

The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's Erleada for use in prostate cancer patients whose disease has not spread but continues to grow despite hormone therapy.

14 Feb 2018

UPDATE 2-FDA approves J&J prostate cancer treatment

Feb 14 The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's Erleada for use in prostate cancer patients whose disease has not spread but continues to grow despite hormone therapy.

14 Feb 2018

FDA approves J&J prostate cancer treatment

Feb 14 The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's Erleada treatment for use with prostate cancer patients whose cancer has not spread but continues to grow despite hormone therapy.

14 Feb 2018

Drugmaker AbbVie boosts 2018 forecast, shares soar to record high

Drugmaker AbbVie Inc significantly boosted its 2018 earnings forecast on Friday with help from U.S. tax reform and said it hopes to accelerate dividend growth and share buybacks, sending its stock soaring to an all-time high.

26 Jan 2018

Netflix lifts S&P, Nasdaq; J&J, Procter hold Dow in check

NEW YORK U.S. stocks advanced on Tuesday, as strong results from Netflix helped lift the S&P and Nasdaq Composite, but the Dow Industrials were hemmed in by declines in Johnson & Johnson and Procter & Gamble. | Video

23 Jan 2018

Deals of the day-Mergers and acquisitions

Jan 23 The following bids, mergers, acquisitions and disposals were reported by 2030 GMT on Tuesday:

23 Jan 2018

US STOCKS-S&P, Nasdaq get Netflix boost; Dow dragged by J&J, Procter

* Dow down 0.07 pct, S&P 500 up 0.15 pct, Nasdaq up 0.56 pct (Updates to mid-afternoon, changes byline)

23 Jan 2018

U.S. appeals court upholds ruling invalidating J&J patent on Remicade

A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J’s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug.

23 Jan 2018

New York City sues drug companies over opioid epidemic

NEW YORK New York City on Tuesday sued eight companies that make or distribute prescription opioids, blaming them for fuelling a deadly epidemic afflicting the most populous U.S. city.

23 Jan 2018

Earnings vs. Estimates